Katherine Ingrid Sprinz, PhD

• Strategic Leadership: Designed and executed the Phase 3 medical affairs strategy and tactical plans for the birtamimab program targeting AL amyloidosis, including launch readiness, field engagement, competitive scenario planning, health economics and outcomes research (HEOR), and patient advocacy initiatives. • Program Development: Built the company's first Expanded Access Program (EAP), Medical Review Committee (MRC), grants, publication processes, and compliance procedures, establishing best practices and driving organizational excellence. • Scientific Leadership: Authored a patent based on data exploration activities from legacy datasets and led HEOR studies, contributing to publication strategies, planning, and real-world evidence generation. • Expertise and Insights: Quickly established as the company’s medical expert in AL amyloidosis, clinical programs, and disease state knowledge, delivering strategic insights for Alliance management, HCP and OL engagement, patient advocacy, and cross-functional initiatives. • Cross-Functional Collaboration: Partnered effectively with commercial, corporate communications, investor relations, clinical, and leadership teams to align medical affairs strategies with organizational objectives, enhancing cross-functional decision-making. • Stakeholder Engagement: Developed and maintained strong relationships with key opinion leaders (KOLs), healthcare professionals (HCPs), and patient advocacy groups to generate actionable insights and foster trust in the therapeutic area community. • Medical Communications: Led the development of scientific communications, grants, and continuing medical education (CME) initiatives to support education and awareness in AL amyloidosis.

• Built and executed global medical affairs strategies, including patient adherence solutions, publication/congress strategies, and KOL engagement. • Developed the program’s first-generation scientific platform, publication compliance processes, and medical advocacy support. • Delivered strategic insights into clinical study design and patient organization collaborations, enhancing program impact and stakeholder engagement.

Global Medical Director within Medical Affairs, responsible for overseeing both the strategic and operations aspects of running the Global Medical Affairs organization by providing vision, strategic leadership, and mentoring to support the organization and internal/external stakeholders. Developing and leading the following strategic medical affairs tactics and operations: • Medical Leadership: Strategic and tactical global medical affairs and brand planning, insights generation, medical reviewer within promotional and medical review committee, medical representative on internal review committee for grants, CMEs, ISR/ISTs, and sponsorships review and approval, competitive intelligence gathering and literature reporting, providing medical expertise as a resource for cross-functional stakeholders, building HCP relationships and collaborations, building compliant processes, systems, and platforms to bring the organization to the next level, and owning and executing on budget planning, contracts, and HCP tiering/FMV determination • Scientific Communications o Publications: leading the strategy and execution of clinical and preclinical publications, finding data gaps, building evidence generation plans, and building the publication process/SOPs o Congress strategy and communications o Medical communications: scientific platform development, publication/congress plan development, booth assets (study cards, disease state videos, corporate assets, pipelines), MSL engagement assets (slide decks, handouts) • Medical Information: process, SRL development, and coordination with key stakeholders • Medical Training for non-sales new hires. Lead the development of training modules, curriculum, and assessments • Management: leading and mentoring reports and colleagues to foster career development and engagement

Global Scientific Communications Lead of a Rare Bleeding Disorders team (team of 4), responsible for engagement and alignment with cross-functional stakeholders while directing strategy of medical communications, publications, congresses, and budget management for five therapeutic areas: acquired Thrombotic Thrombocytopenic Purpura (aTTP), Cold Agglutinin Disease (CAD), Idiopathic Thrombocytopenia (ITP), Sickle Cell Disease (SCD), and beta-Thalassemia (bT).  Strategy: o Managing scientific engagement strategy of five therapeutic areas with products in different life cycle phases: pipeline, pre-launch, post-US/EU launch to ensure appropriate execution of disease state/product education and data dissemination to internal and external stakeholders o Aligning with core stakeholders (medical (global, US, regional affiliates), commercial, field teams, life cycle management, health economics, competitive intelligence, legal, regulatory, patient advocacy, etc.) and leading workstreams and deliverables as part of brand planning and strategy development to communicate on disease burden, unmet need, clinical trial data, therapeutic technology (gene therapy)/mechanism of action  Team leader: o Engaging team to deliver high quality deliverables, remove obstacles, while advancing their growth and knowledge base o Management of external vendors/agencies to ensure initiatives and deliverables are received and timelines are met

Global Scientific Communications Leader for Rare Bleeding Disorders team, responsible for engaging cross-functional stakeholders while leading medical communications, publications, and congresses for aTTP, CAD, ITP, SCD, and bT  Publications: o Managing development of pre-clinical, clinical, and RWE publications: manuscripts, congress abstracts, posters, and oral presentations. o Created publication teams and developed 1st-generation publications plans for CAD/ITP/sutimlimab and aTTP/caplacizumab.  Medical communications: o Scientific communication platforms, slide decks, literature searches and updates, KOL speaker/symposia presentations, MOD videos, and symposia booklets. o Field-based training materials: backgrounders, Q&As, talking points, slide decks o Steering development of the US Sanofi Medical Affairs website for the Rare Blood Disorders franchise, where US HCPS can find information on our therapeutic areas, publications, education, MSLs, congress events, and pipeline.  Congress Strategy: o Leading congress workstreams: sponsorships, booth strategy, medical information/MSL materials, booth materials such as infographics, MOD, videos, interactive pipelines, myth & fact pieces, leave behinds. o Leading Industry Updates, ancillary meetings, patient advocacy speaking engagements, internal training meetings

By utilizing my expertise and background in hemostasis, hemophilia and cardiovascular disease, I am developing, supporting and reviewing the scientific content in slide decks, educational resources, and publications for our pharmaceutical client’s medical affairs bleeding disorder portfolio. I have attended and supported ad boards while striving to build relationships with the client, KOLs, and health care advisors.

I was an adjunct professor leading a 6-credit “Introduction to Biology” course within the Science, Technology, Engineering and Mathematics Department, where I developed multimedia lectures on the general principles of biology, chemistry, genetics and anatomy, and led the accompanying laboratory section.

Leveraging my broad range of therapeutic area expertise, I am partnering with medical agencies, biotechnology and pharmaceutical companies to help them develop medical education platforms, communication strategies, and content writing. I have initiated, created and developed promotional and educational content for physicians and patients; including webinars and sales force materials. I have led KOL activities, including: KOL identification and networking, advisory board and symposia slide deck development and meeting execution, and case study development. I have also compiled medical research, presentation editing, annotation, and proposal development.

I am the in vitro Biology Lead for a biologics program where I define strategy, collaborate with partner lines, and initiated relationships and collaborations with key opinion leaders to understand standard-of-care practices, knowledge gaps, project feasibility, and indication positioning in order to fully evaluate proprietary therapeutic approaches leading to identification/characterization of a lead molecule. I am also the research project lead where I directed a multi-disciplinary preclinical project team and initiated collaborations with top academic universities to drive the program forward by acquiring necessary reagents, developing biomarker endpoints, designed in vivo mechanistic and efficacy studies, and developed experimental plans to fill knowledge gaps. As the lead in vitro biochemist within the Cardiovascular/Hemophilia department, one of my goals was to establish the biological and mechanistic strategies to enable the execution and prioritization of the cardio-renal portfolio. My expertise in protein engineering, expression, purification, and characterization efforts led to the advancement half-life extension programs for several hemostasis Factor replacement programs. I was appointed the CVMED Exploratory Portfolio Point-of-Contact to prioritize and align assay development efforts in order to make decisions on resource allocation and budget allowance in junction with Chemistry, Assay Development, and External Research groups. I also contributed to the advancement of the CV portfolio by new target identification, perform due diligence around external licensing opportunities by critically evaluating research proposals. I participated in a scientific writing workshop: Making Sense of the Science: A Workshop in Scientific Writing from the Readers’ Perspective by Judith A. Swan, Ph.D. In 2014, I was recognized company-wide for my abilities to manage masters’-level associates to meet both their performance objectives and their career objectives.

Advisor: Professor Andrew D. Hamilton, Depts. of Chemistry and Molecular Biophysics and Biochemistry, Dissertation: Molecular Recognition of Protein Surfaces by Rational and Combinatorial Methods * Business Management Study Group, Yale University, New Haven, CT Topics include: Introduction to Financial Accounting, Introduction to Managerial Accounting & Control, Introduction to Operations Management, Introduction to Competitive Strategy, Marketing Strategy and Introduction to Finance